# Trastuzumab Emtansine

## Kadcyla inj 100mg

##### 臨採

| 藥品代碼   | IKAD1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 用法用量   | 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.                                                                                                |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 禁忌       | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 副作用     | Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity， Increased liver enzymes， Grades 3 and 4 (8% )， Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease， Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% )， Interstitial lung disease， Pneumonitis (0.8% to 1.2% ) |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## KADCYLA inj 160mg

##### 臨採

| 藥品代碼   | IKAD6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Metastatic breast cancer， HER2 overexpression， monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 用法用量   | 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.                                                                                                |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 禁忌       | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 副作用     | Common ■Gastrointestinal: Constipation (26.5% )， Nausea (39.8% ) ■Hematologic: Thrombocytopenia， All grades (31.2% ) ■Hepatic: Increased liver enzymes， All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia， Grade 3 and 4 (4.1% )， Neutropenia， Grade 3 and 4 (2% )， Thrombocytopenia， Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity， Increased liver enzymes， Grades 3 and 4 (8% )， Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease， Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% )， Interstitial lung disease， Pneumonitis (0.8% to 1.2% ) |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

